Vivet Therapeutics is committed to developing an innovative liver-directed gene therapy platform for the treatment of rare and severe inherited metabolic disorders. The company's development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes. Vivet's focus is on developing innovative gene therapy technologies and treatments for Wilson disease, Progressive Familiar Intrahepatic Cholestasis, Cirtullinemia and other indications. Vivet's platform leverages new AAV-serotypes, advanced GMP manufacturing processes, disease models and innovative technologies to address current challenges in AAV-based gene therapy.